Published

A phase 1 study of a second experience with Group Retreat Psilocybin Therapy for partial responders after a first experience

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Frontiers in Public Health
Date: 2026-04-14
Source: Crossref
DOI: 10.3389/fpubh.2026.1810904
PubMed: 42058096

Authors

Back Anthony L.McGregor Bonnie A.Thorn Leslie L.Harvey Kalin Blom Dianna Callan George Guy John Kumar Sameet Hershberg Rob Layer Melissa Levin Jackie Myers Susanna Perez Juliana Salmonson Kathy Thompson Peter Whinney Joseph

Watch author

Derived topics and classifications

psilocybin Depression Anxiety Headache / Migraine Mystical Experience Clinical Trial Cancer Patients Safety Adverse Events Clinical Trial

Citation graph

31 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

10.3389/fpsyt.2023.1293243 10.1556/2054.2019.015 10.1016/j.genhosppsych.2025.07.020 10.1177/0269881116675513 10.1016/j.jad.2018.09.027 10.3109/09540261.2013.842542 10.3389/fpsyt.2022.1025726 10.1177/0269881116675512 10.1080/02791072.2019.1593559 10.1177/28314425251413856.10.1177/28314425251404460.10.1176/appi.ajp.20221043

Indexed papers citing this DOI

A phase 1 study of a second experience with Group Retreat Psilocybin Therapy for partial responders after a first experience2026-04-14

Related papers

LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders: a Randomized, Double-blind, Placebo-controlled Phase II StudyClinicalTrials.gov · 2021-12-22 Psilocybin may help cancer patients with depression and anxiety for yearsAccess Science · 2020-01-01 The Utility of Psilocybin in Managing Anxiety and Depression in Cancer PatientsBiochemistry and Molecular Biology Education · 2018-08-01